Literature DB >> 25355421

Expression inactivation of SMARCA4 by microRNAs in lung tumors.

Isabel F Coira1, Eva E Rufino-Palomares1, Octavio A Romero2, Paola Peinado1, Chanatip Metheetrairut3, Laura Boyero-Corral1, Julian Carretero4, Esther Farez-Vidal5, Marta Cuadros5, Fernando J Reyes-Zurita5, Jose A Lupiáñez5, Montse Sánchez-Cespedes2, Frank J Slack3, Pedro P Medina6.   

Abstract

SMARCA4 is the catalytic subunit of the SWI/SNF chromatin-remodeling complex, which alters the interactions between DNA and histones and modifies the availability of the DNA for transcription. The latest deep sequencing of tumor genomes has reinforced the important and ubiquitous tumor suppressor role of the SWI/SNF complex in cancer. However, although SWI/SNF complex plays a key role in gene expression, the regulation of this complex itself is poorly understood. Significantly, an understanding of the regulation of SMARCA4 expression has gained in importance due to recent proposals incorporating it in therapeutic strategies that use synthetic lethal interactions between SMARCA4-MAX and SMARCA4-SMARCA2. In this report, we found that the loss of expression of SMARCA4 observed in some primary lung tumors, whose mechanism was largely unknown, can be explained, at least partially by the activity of microRNAs (miRNAs). We reveal that SMARCA4 expression is regulated by miR-101, miR-199 and especially miR-155 through their binding to two alternative 3'UTRs. Importantly, our experiments suggest that the oncogenic properties of miR-155 in lung cancer can be largely explained by its role inhibiting SMARCA4. This new discovered functional relationship could explain the poor prognosis displayed by patients that independently have high miR-155 and low SMARCA4 expression levels. In addition, these results could lead to application of incipient miRNA technology to the aforementioned synthetic lethal therapeutic strategies.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25355421      PMCID: PMC4321447          DOI: 10.1093/hmg/ddu554

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  33 in total

1.  Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells.

Authors:  Pedro P Medina; Julian Carretero; Esteban Ballestar; Barbara Angulo; Fernando Lopez-Rios; Manel Esteller; Montserrat Sanchez-Cespedes
Journal:  Hum Mol Genet       Date:  2005-02-24       Impact factor: 6.150

2.  Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.

Authors:  Pedro P Medina; Octavio A Romero; Takashi Kohno; Luis M Montuenga; Ruben Pio; Jun Yokota; Montse Sanchez-Cespedes
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

3.  Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer.

Authors:  Junya Fukuoka; Takeshi Fujii; Joanna H Shih; Tatiana Dracheva; Daoud Meerzaman; Audrey Player; Kyeong Hong; Sharon Settnek; Ajay Gupta; Kenneth Buetow; Stephen Hewitt; William D Travis; Jin Jen
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

4.  Identifying targets for the restoration and reactivation of BRM.

Authors:  B Kahali; S J B Gramling; S B Marquez; K Thompson; L Lu; D Reisman
Journal:  Oncogene       Date:  2013-03-25       Impact factor: 9.867

5.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

6.  Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis.

Authors:  David N Reisman; Janiece Sciarrotta; Weidong Wang; William K Funkhouser; Bernard E Weissman
Journal:  Cancer Res       Date:  2003-02-01       Impact factor: 12.701

Review 7.  microRNAs and cancer: an overview.

Authors:  Pedro P Medina; Frank J Slack
Journal:  Cell Cycle       Date:  2008-08-17       Impact factor: 4.534

8.  Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.

Authors:  Cigall Kadoch; Diana C Hargreaves; Courtney Hodges; Laura Elias; Lena Ho; Jeff Ranish; Gerald R Crabtree
Journal:  Nat Genet       Date:  2013-05-05       Impact factor: 38.330

9.  Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice.

Authors:  Stefan Costinean; Sukhinder K Sandhu; Irene M Pedersen; Esmerina Tili; Rossana Trotta; Danilo Perrotti; David Ciarlariello; Paolo Neviani; Jason Harb; Lauren Rachel Kauffman; Aaditya Shidham; Carlo Maria Croce
Journal:  Blood       Date:  2009-06-11       Impact factor: 22.113

10.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

View more
  11 in total

Review 1.  Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors.

Authors:  Kyriakos Chatzopoulos; Jennifer M Boland
Journal:  Virchows Arch       Date:  2021-01-06       Impact factor: 4.064

2.  Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities.

Authors:  Akihiko Yoshida; Eisuke Kobayashi; Takashi Kubo; Makoto Kodaira; Toru Motoi; Noriko Motoi; Kan Yonemori; Yuichiro Ohe; Shun-Ichi Watanabe; Akira Kawai; Takashi Kohno; Hiroshi Kishimoto; Hitoshi Ichikawa; Nobuyoshi Hiraoka
Journal:  Mod Pathol       Date:  2017-03-03       Impact factor: 7.842

3.  BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines.

Authors:  M Cuadros; V Sánchez-Martín; A Herrera; C Baliñas; J Martín-Padrón; L Boyero; P Peinado; P P Medina
Journal:  Clin Transl Oncol       Date:  2017-03-01       Impact factor: 3.405

4.  Tumor progression by epithelial-mesenchymal transition in ARID1A- and SMARCA4-aberrant solid-type poorly differentiated gastric adenocarcinoma.

Authors:  Taisuke Sasaki; Kenichi Kohashi; Shinichiro Kawatoko; Eikichi Ihara; Eiji Oki; Masafumi Nakamura; Yoshihiro Ogawa; Yoshinao Oda
Journal:  Virchows Arch       Date:  2022-01-08       Impact factor: 4.064

5.  SWI/SNF proteins as targets in cancer therapy.

Authors:  Santiago Schiaffino-Ortega; Carlos Balinas; Marta Cuadros; Pedro P Medina
Journal:  J Hematol Oncol       Date:  2014-11-13       Impact factor: 17.388

6.  Activation of Galectin-3 (LGALS3) Transcription by Injurious Stimuli in the Liver Is Commonly Mediated by BRG1.

Authors:  Zilong Li; Fangqiao Lv; Congxin Dai; Qiong Wang; Chao Jiang; Mingming Fang; Yong Xu
Journal:  Front Cell Dev Biol       Date:  2019-11-26

7.  Comprehensive Analysis of SWI/SNF Inactivation in Lung Adenocarcinoma Cell Models.

Authors:  Paola Peinado; Alvaro Andrades; Marta Cuadros; Maria Isabel Rodriguez; Isabel F Coira; Daniel J Garcia; Juan Carlos Álvarez-Perez; Carlos Baliñas-Gavira; Alberto M Arenas; Juan Rodrigo Patiño-Mercau; Juan Sanjuan-Hidalgo; Octavio A Romero; Luis M Montuenga; Julian Carretero; Montserrat Sanchez-Cespedes; Pedro P Medina
Journal:  Cancers (Basel)       Date:  2020-12-10       Impact factor: 6.639

8.  GABPB1-AS1 Promotes the Development of Osteosarcoma by Targeting SP1 and Activating the Wnt/β-Catenin Pathway.

Authors:  Jingyang Chen; Meiru Bian; Lingxiao Pan; Chengdong Liu; Hanshi Yang
Journal:  J Oncol       Date:  2022-03-18       Impact factor: 4.375

9.  A functional variant in miR-155 regulation region contributes to lung cancer risk and survival.

Authors:  Kaipeng Xie; Hongxia Ma; Cheng Liang; Cheng Wang; Na Qin; Wei Shen; Yayun Gu; Caiwang Yan; Kai Zhang; Ningbin Dai; Meng Zhu; Shuangshuang Wu; Hui Wang; Juncheng Dai; Guangfu Jin; Hongbing Shen; Zhibin Hu
Journal:  Oncotarget       Date:  2015-12-15

Review 10.  The Role of BRG1 in Antioxidant and Redox Signaling.

Authors:  Shilong You; Ying Zhang; Jiaqi Xu; Hao Qian; Shaojun Wu; Boquan Wu; Saien Lu; Yingxian Sun; Naijin Zhang
Journal:  Oxid Med Cell Longev       Date:  2020-09-14       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.